ImpediMed Limited (IPDQF)

Market Cap	13.22M -74.6%
Revenue (ttm)	10.11M +14.8%
Net Income	-17.23M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,916
Open	0.0040
Previous Close	0.0040
Day's Range	0.0040 - 0.0040
52-Week Range	0.0033 - 0.0409
Beta	1.06
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 27, 2026

About ImpediMed

ImpediMed Limited, a medical technology company, engages in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services in Australia, Europe, North America, and internationally. The company offers SOZO Digital Health Platform which transforms fluid status and tissue composition into insights with a single scan; L-Dex Analysis for Lymphedema, designed for early lymphedema detection; BodyComp Analysis; Segmental BodyComp Analysis; and HF-Dex Analysis for Heart Failure. It also provides Lymphedema Preven...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1999
• Employees: 66
• Stock Exchange: OTCMKTS
• Ticker Symbol: IPDQF

Financial Performance

In fiscal year 2026, ImpediMed's revenue was 14.61 million, an increase of 14.85% compared to the previous year's 12.72 million. Losses were -24.91 million, 7.19% more than in 2025.

Financial numbers in AUD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 7, 2026

Data Sources Report a data error